Study of risankizumab for moderate to severe ulcerative colitis in Japan
Part of Digestive system clinical trials.
This study looks at how well risankizumab (an injected medicine) works for people with moderate to severe ulcerative colitis. It tracks your symptoms using a mobile app to see if the drug helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe ulcerative colitis
- Your doctor has decided to prescribe risankizumab as part of your routine care, before you join the study
- You have never taken risankizumab before
- You can use a smartphone to answer questions about your symptoms
- You are not in another research study that involves treatment
- You can give consent (or a parent/guardian can if you are under 18)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes how well risankizumab works for people with moderate to severe ulcerative colitis who are already starting it as part of their regular care. It helps doctors learn more about the drug's real-world effects.
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This Phase 1 study tests whether R-3750 is safe in people with mild to moderate ulcerative colitis and looks for early signs it could help. You may be able to join if you have stable treatment, confirmed diagnosis, and meet several health and medication timing rules.
This trial tests a new imaging method using a special dye (risankizumab-800CW) to see how risankizumab, a medicine for inflammatory bowel disease, works in the bowel. The goal is to better understand the medicine's effects and help doctors tailor treatments.
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.